Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer

NCT00106262 is registered in ClinicalTrials.gov with Women and Infants Hospital of Rhode Island as lead sponsor.

NCT NCT00106262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer
Lead sponsor
Women and Infants Hospital of Rhode Island
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2005
Completion date
March 31, 2007
Enrollment
38
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer